JP2025516335A - オートタキシン阻害剤の多形形態 - Google Patents
オートタキシン阻害剤の多形形態 Download PDFInfo
- Publication number
- JP2025516335A JP2025516335A JP2024565103A JP2024565103A JP2025516335A JP 2025516335 A JP2025516335 A JP 2025516335A JP 2024565103 A JP2024565103 A JP 2024565103A JP 2024565103 A JP2024565103 A JP 2024565103A JP 2025516335 A JP2025516335 A JP 2025516335A
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- compound
- approximately
- degrees
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364065P | 2022-05-03 | 2022-05-03 | |
| US63/364,065 | 2022-05-03 | ||
| PCT/US2023/020428 WO2023215196A1 (en) | 2022-05-03 | 2023-04-28 | Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516335A true JP2025516335A (ja) | 2025-05-27 |
| JP2025516335A5 JP2025516335A5 (cg-RX-API-DMAC10.html) | 2026-05-11 |
Family
ID=88646878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565103A Pending JP2025516335A (ja) | 2022-05-03 | 2023-04-28 | オートタキシン阻害剤の多形形態 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250282759A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4519253A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025516335A (cg-RX-API-DMAC10.html) |
| CN (1) | CN120112527A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023265017A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3251769A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023215196A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160654A1 (es) * | 2013-11-22 | 2016-07-15 | Pharmakea Inc | Compuestos de inhibidor de autotaxina |
| CN116059203A (zh) * | 2015-05-27 | 2023-05-05 | 赛博治疗有限责任公司 | 自分泌运动因子抑制剂及其用途 |
-
2023
- 2023-04-28 AU AU2023265017A patent/AU2023265017A1/en active Pending
- 2023-04-28 US US18/862,461 patent/US20250282759A1/en active Pending
- 2023-04-28 CN CN202380049621.6A patent/CN120112527A/zh active Pending
- 2023-04-28 CA CA3251769A patent/CA3251769A1/en active Pending
- 2023-04-28 EP EP23799859.6A patent/EP4519253A4/en active Pending
- 2023-04-28 JP JP2024565103A patent/JP2025516335A/ja active Pending
- 2023-04-28 WO PCT/US2023/020428 patent/WO2023215196A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023215196A1 (en) | 2023-11-09 |
| US20250282759A1 (en) | 2025-09-11 |
| CN120112527A (zh) | 2025-06-06 |
| EP4519253A4 (en) | 2026-06-10 |
| EP4519253A1 (en) | 2025-03-12 |
| CA3251769A1 (en) | 2023-11-09 |
| AU2023265017A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7274521B2 (ja) | オートタキシン阻害剤とその使用 | |
| US11136325B2 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives | |
| JP6851825B2 (ja) | 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体 | |
| CN107454898B (zh) | 生长素释放肽o-酰基转移酶抑制剂 | |
| JP7025555B2 (ja) | 一過性受容体電位a1イオンチャネルの阻害 | |
| US20250282759A1 (en) | Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat | |
| JP2025526320A (ja) | 治療用の化合物、製剤、およびその使用 | |
| AU2019292207B2 (en) | Pyridopyrimidinone derivatives for use as Axl inhibitors | |
| CN104788423B (zh) | 一种新的囊性纤维化跨膜传导调节因子抑制剂 | |
| JP6843845B2 (ja) | 1,4−ジ−(4−メチルチオフェニル)−3−フタロイルアゼチジン−2−オンおよびその誘導体 | |
| US11987582B2 (en) | Maleate salts of triazolopyrazine derivatives, compositions, methods of use, and processes of manufacturing the same | |
| HK40077153A (en) | Autotaxin inhibitors and uses thereof | |
| EA047522B1 (ru) | Комбинация антагониста азетидиновых рецепторов lpa1 с пирфенидоном и/или нинтеданибом для применения для лечения фиброзных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260427 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260427 |